By using proprietary yeast cells to deliver mRNA to the gut, which houses a significant portion of the body's immune system, Esperovax's oral capsule vaccines enable the rapid development of cost-effective vaccines that can be taken by consumers without the need for a healthcare professional. Founded in 2018 and based in Plymouth, Michigan, Esperovax aims to become the global leader in oral tablet/capsule vaccinations for some of the world's deadliest treatable diseases.